Battle Card: Oligomerix Capital Push
Caple’s chair election sparks a biotech capital push. Fuel your pipeline with capital-raising and partnership pitches. Close Phase 2 funding. Schedule next touch now.
Published on
Do not index
Do not index
🚀 Battle Card: Oligomerix, Inc.
Quick trigger:
This Oligomerix, Inc. sales trigger underscores a finance-heavy agenda.
👤 Decision Maker in the News
- William Caple, Chairman of the Board · 🔗 LinkedIn
💡 Why It Matters
- Adding a chairman with deep capital markets and M&A experience signals a push to secure new financing and strategic partnerships.
- This Oligomerix, Inc. sales trigger reveals urgency on securing investor consortiums. → Source
🎯 Core Pain Point
- Securing growth capital for Phase 1/2 development
- Building strategic alliances and investor consortiums
💰 What to Pitch
- Primary: Biotech capital-raising advisory → Accelerate funding for Phase 2 trials
- Expansion: Strategic partnership facilitation → Establish consortium of investors and partners Leverage this Oligomerix, Inc. sales trigger to lead with capital partnering solutions.
🗺️ Quick Context
- HQ: Bronx, NY
- Employees: ≈ 50
- Rev: ≈ $3 M
- Website: oligomerix.com Use this Oligomerix, Inc. sales trigger to time your pitch around funding and partnerships.
🤼 Competitive Intel
*Which other vendors you’ll probably face to win **Oligomerix, Inc.*’s business.
- SVB Securities — Biotech investment banking
- Unique edge: Deep ties to life science VC networks
- Evaluated by CFO for lead investor sourcing
- Jefferies — Life sciences advisory
- Unique edge: Global placement services for clinical-stage firms
- Evaluated by President & CEO for valuation expertise
- Piper Sandler — Healthcare investment banking
- Unique edge: Robust equity and debt structuring capabilities
- Evaluated by VP Finance for deal execution speed
- Houlihan Lokey — M&A and capital advisory
- Unique edge: Boutique focus on middle-market biotech
- Evaluated by CFO for bespoke M&A strategies
✅ Do-Now Checklist
Connect with all decision makers on LinkedIn (links above)
Generate email + DM with the Copy-My-Prompt block (Step 7) and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Tie your outreach to this Oligomerix, Inc. sales trigger for relevance
Next Step
Get intel like this daily—no fluff, all pipeline.
Don’t miss another Oligomerix, Inc. sales trigger—**Subscribe to NewsletterForLeads**
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑ ❑
OFFER_BRIEF = ❑Biotech capital-raising advisory❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = William
COMPANY = Oligomerix, Inc.
DEPT = Board
SIZE = ≈7
BOTTLENECK = Securing growth capital
EVENT = Elected new chairman
DETAIL = election of William Caple as Chairman
PAIN = Securing growth capital for Phase 1 development
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250903627948&div=41152219
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈15
EMP_EST = ≈50
REV_EST = ≈ $3M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈7-person Board
William—noticed your Board team is ≈7.
That’s when Securing growth capital slows growth.
We helped ≈ TBD fix this with Biotech capital-raising advisory.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈15.
DM ≤45 words, TONE:
Saw your post about election of William Caple as Chairman — Securing growth capital for Phase 1 development.
Biotech capital-raising advisory. ≈ TBD.
Quick chat?